Intrahepatic Cholangiocarcinoma Clinical Trials 2023
Browse 99 Intrahepatic Cholangiocarcinoma Medical Studies Across 273 Cities
9 Phase 3 Trial · 964 Intrahepatic Cholangiocarcinoma Clinics
Reviewed by Michael Gill, B. Sc.
10 Intrahepatic Cholangiocarcinoma Clinical Trials Near Me
Top Hospitals for Intrahepatic Cholangiocarcinoma Clinical Trials
Memorial Sloan Kettering Cancer Center
New York
13Active Trials
25All Time Trials for Intrahepatic Cholangiocarcinoma
2000First Intrahepatic Cholangiocarcinoma Trial
Massachusetts General Hospital
Boston
9Active Trials
19All Time Trials for Intrahepatic Cholangiocarcinoma
2006First Intrahepatic Cholangiocarcinoma Trial
MD Anderson Cancer Center
Houston
8Active Trials
15All Time Trials for Intrahepatic Cholangiocarcinoma
2011First Intrahepatic Cholangiocarcinoma Trial
The University of Texas MD Anderson Cancer Center
Houston
7Active Trials
11All Time Trials for Intrahepatic Cholangiocarcinoma
2014First Intrahepatic Cholangiocarcinoma Trial
Top Cities for Intrahepatic Cholangiocarcinoma Clinical Trials
Intrahepatic Cholangiocarcinoma Clinical Trials by Phase of TrialN/A Intrahepatic Cholangiocarcinoma Clinical Trials
Intrahepatic Cholangiocarcinoma Clinical Trials by Age Group10Active Intrahepatic Cholangiocarcinoma Clinical Trials
10Number of Unique Treatments
9Number of Active Locations
18+ Intrahepatic Cholangiocarcinoma Clinical Trials
Most Recent Intrahepatic Cholangiocarcinoma Clinical Trials98Active Intrahepatic Cholangiocarcinoma Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
9/1/2023
Phase 2
Treatment Name
Active Intrahepatic Cholangiocarcinoma Clinical Trials
All Time Trials for Intrahepatic Cholangiocarcinoma
First Recorded Intrahepatic Cholangiocarcinoma Trial
Gemcitabine
5
47
2002
Durvalumab
2
14
2016
Tivozanib
2
2
2021
Olaparib
2
5
2019
Treatment
2
2
1998
Treatment
Year
Sponsor
CDX-527
2020
Celldex Therapeutics
MVT-5873
2019
National Cancer Institute (NCI)
Trifluridine and Tipiracil Hydrochloride
2019
Mayo Clinic
Mesothelin Expression
2019
National Cancer Institute (NCI)
XmAb®22841
2019
Xencor, Inc.
M7824
2019
EMD Serono Research & Development Institute, Inc.
Part 1 TPST-1120
2019
Tempest Therapeutics
FT-2102
2018
Forma Therapeutics, Inc.
NC318
2018
NextCure, Inc.
Niraparib
2018
University of Florida
About The Author
Michael Gill - B. Sc.
First Published: October 30th, 2021
Last Reviewed: August 31st, 2023
References1 Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205-13. https://pubmed.ncbi.nlm.nih.gov/152735422 Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205-13. doi: 10.1097/01.sla.0000133083.54934.ae. https://pubmed.ncbi.nlm.nih.gov/152735423 Levy PL, Gros A. Fast track to personalized TCR T cell therapies. Cancer Cell. 2022 May 9;40(5):447-449. doi: 10.1016/j.ccell.2022.04.013. Epub 2022 May 9. https://pubmed.ncbi.nlm.nih.gov/355374084 Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, Manzuk L, Piha-Paul SA, Xu L, Zeigenfuss S, Pruitt SK, Leary A. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2019 Jun 10;37(17):1470-1478. doi: 10.1200/JCO.18.01265. Epub 2019 Apr 3. https://pubmed.ncbi.nlm.nih.gov/309431245 Piha-Paul SA, Oh DY, Ueno M, Malka D, Chung HC, Nagrial A, Kelley RK, Ros W, Italiano A, Nakagawa K, Rugo HS, de Braud F, Varga AI, Hansen A, Wang H, Krishnan S, Norwood KG, Doi T. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020 Oct 15;147(8):2190-2198. doi: 10.1002/ijc.33013. Epub 2020 May 2. https://pubmed.ncbi.nlm.nih.gov/323590916 Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M, Penel N, Hansen AR, Piha-Paul SA, Doi T, Gao B, Chung HC, Lopez-Martin J, Bang YJ, Frommer RS, Shah M, Ghori R, Joe AK, Pruitt SK, Diaz LA Jr. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020 Jan 1;38(1):1-10. doi: 10.1200/JCO.19.02105. Epub 2019 Nov 4. https://pubmed.ncbi.nlm.nih.gov/316825507 Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D, D'Angelica M, DeMatteo RP, Fong Y, Schwartz L, Kemeny N, O'Reilly E, Abou-Alfa GK, Shimada H, Blumgart LH, Jarnagin WR. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008 Jul;248(1):84-96. doi: 10.1097/SLA.0b013e318176c4d3. https://pubmed.ncbi.nlm.nih.gov/185802118 Dai C, Liang S, Sun B, Kang J. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas. Front Endocrinol (Lausanne). 2020 Dec 11;11:608422. doi: 10.3389/fendo.2020.608422. eCollection 2020. Review. https://pubmed.ncbi.nlm.nih.gov/333627229 Talreja JP, Kahaleh M. Photodynamic therapy for cholangiocarcinoma. Gut Liver. 2010 Sep;4 Suppl 1(Suppl 1):S62-6. doi: 10.5009/gnl.2010.4.S1.S62. Epub 2010 Sep 10. https://pubmed.ncbi.nlm.nih.gov/2110329710 Talreja JP, DeGaetani M, Sauer BG, Kahaleh M. Photodynamic therapy for unresectable cholangiocarcinoma: contribution of single operator cholangioscopy for targeted treatment. Photochem Photobiol Sci. 2011 Jul;10(7):1233-8. doi: 10.1039/c0pp00259c. Epub 2011 Apr 21. https://pubmed.ncbi.nlm.nih.gov/21512706